DISCLOSURES

This activity is jointly provided by Northwest Portland Area Indian Health Board and Cardea

Cardea Services is approved as a provider of continuing nursing education by Montana Nurses Association, an accredited approver with distinction by the American Nurses Credentialing Center's Commission on Accreditation.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Institute for Medical Quality/California Medical Association (IMQ/CMA) through the joint providership of Cardea and Northwest Portland Area Indian Health Board. Cardea is accredited by the IMQ/CMA to provide continuing medical education for physicians.

Cardea designates this live web-based training for a maximum of 1 AMA PRA Category 1 Credit(s)[™]. Physicians should claim credit commensurate with the extent of their participation in the activity.





DISCLOSURES

COMPLETING THIS ACTIVITY

Upon successful completion of this activity 1 contact hour will be awarded Successful completion of this continuing education activity includes the following:

- Attending the entire CE activity;
- Completing the online evaluation;
- Submitting an online CE request.

Your certificate will be sent via email If you have any questions about this CE activity, contact Michelle Daugherty at <u>mdaugherty@cardeaservices.org</u> or (206) 447-9538



CONFLICT OF INTEREST

Paulina Deming is on an advisory committee for Gilead. None of the other planners or presenters of this CE activity have any relevant financial relationships with any commercial entities pertaining to this activity.



Acknowledgement

This presentation is funded in part by:

The Indian Health Service HIV Program and The Secretary's Minority AIDS Initiative Fund





HCV ECHO® WESTERN STATES

Liver Fibrosis Staging

Paulina Deming, PharmD, PhC Associate Professor of Pharmacy-College of Pharmacy Project ECHO University of New Mexico Health Sciences Center

> Original presentation by: Date prepared:

March 28, 2018









OBJECTIVES

- 1. Describe the stages of hepatitis C related liver disease;
- 2. Identify non-invasive liver fibrosis staging methods




Why is it Important to Stage a Patient's Level of Liver Disease?

- Patients with cirrhosis may require a longer duration of HCV treatment and/or addition of ribavirin
- Patients with cirrhosis require additional evaluation and follow up care
 - Endoscopy for evaluation of varices
 - On-going (and indefinite) surveillance for hepatocellular carcinoma



Hepatitis C: Progression of Disease





Laboratories for Recognizing Fibrosis/Cirrhosis

 Alanine aminotransferase (ALT), aspartate aminotransferase (AST) Recognize level of inflammation and liver injury

 Serum albumin, direct bilirubin, international normalized ratio (INR)

Assess hepatic synthetic function

 Complete blood count with differential

Identify changes consistent with cirrhosis



Why is the CBC Important to Understand Liver Disease Severity?

- Anemia
 - Can indicate complications of cirrhosis
 - Sudden decline in hemoglobin concerning for bleeding
 - Trends in declining hemoglobin concerning for slow bleeding
- Thrombocytopenia (<150 thousand)
 - Due to portal hypertension caused by cirrhosis
 - Portal hypertension causes:
 - Platelets to become "stuck" in spleen
 - More platelets damaged/destroyed
- Neutropenia
 - Cirrhosis can cause bone marrow suppression



Abnormalities in Hepatic Panel

- Elevations in AST or ALT useful for measuring liver cell injury
 - What is normal AST or ALT? 40 IU/mL
 - Studies suggest this is too high and normal should be lower and different for men vs. women
 - Healthy ALT is <30 IU/mL for men and <19 IU/mL for women
- Elevations in conjugated bilirubin suggest liver disease
- Loss of liver's ability to synthesize (lack of synthetic function) can be seen with:
 - Low serum albumin
 - Prolonged prothrombin time (elevated INR)
 - Important to look at trends in labs over time




Findings Suggestive of Advanced Fibrosis/ Cirrhosis

- Presence or history of ascites or esophageal varices
- Low platelet count (<150,000 mm³)
- APRI <u>></u> 1.0
- FIB-4 <u>></u> 3.25
- Fibrosure ≥ 0.72
- Imaging with evidence of cirrhosis (nodular contour of liver or evidence of portal hypertension)
- Liver biopsy with F3 or F4 fibrosis
- Transient elastography consistent with advanced fibrosis/cirrhosis



AST to Platelet Ratio Index (APRI) Calculator

This is an AST to Platelet Ratio Index calculator tool. Enter the required values to calculate the APRI value. The APRI Score will appear in the oval on the far right (highlighted in yellow). Most laboratories use 40 IU/L as the value for the AST upper limit of normal.




Source: Lin ZH, Xin YN, Dong QJ, et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology. 2011;53:726-36.



Fibrosis-4 (FIB-4) Calculator

The Fibrosis-4 score helps to estimate the amount of scarring in the liver. Enter the required values to calculate the FIB-4 value. It will appear in the oval on the far right (highlighted in yellow).



Interpretation:

Using a lower cutoff value of 1.45, a FIB-4 score <1.45 had a negative predictive value of 90% for advanced fibrosis (Ishak fibrosis score 4-6 which includes early bridging fibrosis to cirrhosis). In contrast, a FIB-4 >3.25 would have a 97% specificity and a positive predictive value of 65% for advanced fibrosis. In the patient cohort in which this formula was first validated, at least 70% patients had values <1.45 or >3.25. Authors argued that these individuals could potentially have avoided liver biopsy with an overall accuracy of 86%.

Sources

Sterling RK, Lissen E, Clumeck N, et. al. Development of a simple noninvasive index to predict significant fibrosis patients with HIV/HCV co-infection. Hepatology 2006;43:1317-1325.

https://www.hepatitisc.uw.edu/page/clinical-calculators/fib-4

Project

☑ Share

Child-Pugh Classification of Cirrhosis for Drug Dosing

	1 Point	2 Points	3 Points
Encephalopathy	None	Moderate	Severe
Ascites	Absent	Mild- Moderate	Severe/ Refractory
Bilirubin (mg/dL)	< 2	2 - 3	> 3
Albumin (g/dL)	> 3.5	2.8 - 3.5	< 2.8
INR	<1.7	1.7-2.3	>2.3
(PT Prolongation sec over control)	(0-4)	4-6	(>6)

Child-Pugh Interpretation of Hepatic Function in a Patient with Cirrhosis

C-P Score (Class)	Liver Function	
5-6 (A)	Mild Dysfunction	
7-9 (B)	Moderate Dysfunction Moderate dose reduction (~25%) for drugs that are mostly hepatically metabolized	
> 9 (C)	Severe Dysfunction Significant dose reduction (~50%) for drugs that are mostly hepatically metabolized	


Note: Child Pugh Score is calculated only for patients with cirrhosis

Liver Biopsy is Gold Standard but...


- Liver biopsy is not reliable gold standard
 - Sampling error leads to misinterpretation in 10-15% of cases
 - Can miss the diagnosis of cirrhosis
 - Invasive procedure with complications
 - Expensive
 - Poor patient acceptance
 - Interpretation has significant inter observer variability



Natural History of Chronic Liver Disease



Patients with Cirrhosis Decompensation Shortens Survival



Source: Ginés P, et al. Hepatology 1987; 7:122-8.

Summary

- Important to recognize cirrhosis for medical management of HCV and for management of complications associated with chronic liver disease
- Advanced fibrosis/cirrhosis can be identified by
 - Minimally invasive tests including laboratories
 - Scoring systems utilizing laboratories
 - Imaging
 - Transient elastography
- Role of biopsy diminished in identifying cirrhosis





HCV ECHO[®] WESTERN STATES

End of Presentation

Questions?







